BioLingus (Cayman) Limited (SUBL)
BioLingus (Cayman) Limited will go public soon, but the exact IPO date is still unknown.
IPO Price
$20.00
Shares Offered
360,000
Deal Size
$7.20M

SUBL Income Statement

Millions USD. Fiscal year is May - Apr.
Year 20222021
Selling, General & Admin
1.11.55
Research & Development
0.270.36
Operating Expenses
1.371.91
Operating Income
-1.37-1.91
Interest Expense / Income
0.20.11
Other Expense / Income
-0.150.01
Pretax Income
-1.42-2.03
Net Income
-1.42-2.03
Free Cash Flow
-0.55-1.65
EBITDA
-1.06-1.7
Depreciation & Amortization
0.160.22
EBIT
-1.22-1.92
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).